Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection (Q57181637)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

3 December 2019

main subject

1 reference

inferred from title

lamivudine/zidovudine

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

J V Chancellor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

A M Hill

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

K N Simpson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M Youle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

54-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

The economic costs of caring for people with HIV infection and AIDS in England and Wales

3 December 2019

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Will we ever know when to treat HIV infection?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Cost and utilisation of community services for people with HIV infection in London.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Cost effectiveness analysis of early zidovudine treatment of HIV infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Zidovudine therapy and health resource utilization in AIDS

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

The cumulative risk of AIDS as the CD4 lymphocyte count declines

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

The Markov process in medical prognosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/10169387

12 December 2020

10.2165/00019053-199712010-00006

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10169387%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 December 2019

1003832056

0 references

1 reference